4-cycloheptenecarboxaldehyde | 2401-88-9

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机氧化物
• 英文名称: 4-cycloheptenecarboxaldehyde
• 英文别名: cis-1-formyl-4-cycloheptene；cyclohept-4-enecarbaldehyde；Cyclohepten-(4)-formaldehyd；Cyclohept-4-en-aldehyd；Cyclohept-4-enecarboxaldehyde；cyclohept-4-ene-1-carbaldehyde
• CAS: 2401-88-9
• 化学式: C₈H₁₂O
• 分子量: 124.183
• InChiKey: QYTGOKJETKZZAM-UHFFFAOYSA-N

物化性质

• 沸点：
  74 °C(Press: 10 Torr)
• 密度：
  1.000±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-cycloheptenecarboxaldehyde 在 氨 、 silver(l) oxide 作用下， 反应 10.0h， 以84%的产率得到4-cycloheptene-1-carboxylic acid
  参考文献：
  名称：

  Zakharkin, L. I.; Guseva, V. V.; Kamernitskii, D. A., Journal of Organic Chemistry USSR (English Translation), 1989, vol. 25, # 1.1, p. 99 - 102

  摘要：

  DOI：
• 作为产物：
  描述：

  4-cycloheptene-1-carboxylic acid 在 lithium aluminium tetrahydride 、 pyridinium chlorochromate 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 6.0h， 生成 4-cycloheptenecarboxaldehyde
  参考文献：
  名称：

  Thermal rearrangement of 3-methylenespiro[5.6]dodeca-1,4,9-triene and spiro[5.6]dodeca-1,4,9-trien-3-one

  摘要：

  DOI：

  10.1021/jo00351a001

文献信息

• PROCESS FOR PREPARING PURE CYCLODODECANONE
  申请人：Teles Joaquim Henrique

  公开号：US20100191018A1

  公开（公告）日：2010-07-29

  The present invention relates to a process for preparing at least one cyclic compound with Z cycles and 7 to 16 carbon atoms with a keto group, at least comprising the stages: (a1) oxidation of a composition (A), at least comprising one cyclic olefin with Z cycles and 7 to 16 carbon atoms and at least two C—C double bonds, by means of dinitrogen monoxide to give a composition (A1), (a2) separating off the at least one cyclic olefin with Z cycles and 7 to 16 carbon atoms with at least two C—C double bonds from the composition (A1) in order to obtain a composition (A2), and (b) distillative treatment of the composition (A2) from step (a2) in order to obtain a composition (B), comprising the at least one cyclic compound with Z cycles and 7 to 16 carbon atoms with a keto group and less than 1.0% by weight of the at least one compound with Z−1 cycles and 7 to 16 carbon atoms with at least one aldehyde group, where Z can be 1, 2, 3 or 4.

  本发明涉及一种制备至少一种具有Z个环和7到16个碳原子的含酮基的环状化合物的方法，至少包括以下阶段：(a1)将含有至少一种具有Z个环和7到16个碳原子以及至少两个C—C双键的环状烯烃的组合物（A）氧化，通过二氧化二氮，得到组合物（A1）；(a2)从组合物（A1）中分离出至少一种具有Z个环和7到16个碳原子以及至少两个C—C双键的环状烯烃，以获得组合物（A2）；以及(b)对来自步骤（a2）的组合物（A2）进行蒸馏处理，以获得组合物（B），包括具有Z个环和7到16个碳原子的至少一种含酮基的环状化合物，以及少于1.0%的重量的至少一种含有Z−1个环和7到16个碳原子且至少一个醛基的化合物，其中Z可以为1、2、3或4。
• [EN] GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS<br/>[FR] LIGANDS DES RECEPTEURS DE LA GASTRINE ET DE LA CHOLECYSTOKININE
  申请人：BLACK JAMES FOUNDATION

  公开号：WO2000027823A1

  公开（公告）日：2000-05-18

  Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently =N-, -N(R5)- =CH-, -S- or -O-. n is from 1 to 4; R1 is H or C¿1? to C15 hydrocarbyl R?2¿ is selected from H, Me, Et, Pr and OH, R¿3? is selected from H, Me, Et and Pr; or (when n is greater than 1) each R?3¿ is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C¿3? to C6 carbocylic ring, or R?2 and R3¿ on the same carbon atom together represent an =O group; R4 is C1 to C15 hydrocarbyl Z is -(NR7)a-CO-(NR8)b- (wherein a is 0 or 1, b is 0 or 1, -CO-NR7-CH2-CO-NR8-, -CO-O-, -CH¿2?-CH2-, -CH=CH-, -CH2-NR?8¿- or a bond; Q is -R9V, or (II), (wherein R9 is -CH¿2?-; -CH2-CH2-; or (III), R?9 and R8¿, together with the nitrogen atom to which R8 is attached, form a piperidine or pyrrolidine ring which is substituted by V; V is -CO-NH-SO¿2?-Ph, -SO2-NH-CO-Ph, -CH2OH, or a group of the formula -R?10¿U, (wherein U is -COOH, tetrazolyl, -CONHOH- or -SO¿3?H; and R?10¿ is a bond; C¿1? to C6 hydrocarbylene, -O-(C1 to C3 alkylene)-; -SO2NR?11-CHR12¿-; -CO-NR?11-CHR12¿-, or -NH-(CO)¿c?-CH2-, c being 0 or 1).

  式(I)化合物及其药学上可接受的盐是胃泌素和/或胆囊收缩素受体的配体。X和Y独立地为=N-，-N（R5）-，=CH-，-S-或-O-。n为1至4；R1为H或C1至C15的烃基；R2从H，Me，Et，Pr和OH中选择，R3从H，Me，Et和Pr中选择；或（当n大于1时）每个R3独立地从H，Me，Et和Pr中选择，或相邻碳原子上的两个R3基团连接形成C3至C6的环烷基，或R2和R3在同一碳原子上共同表示一个=O基团；R4为C1至C15的烃基，Z为-(NR7)a-CO-(NR8)b-（其中a为0或1，b为0或1，-CO-NR7-CH2-CO-NR8-，-CO-O-，-CH2-CH2-，-CH=CH-，-CH2-NR8-或键；Q为-R9V，或（II），（其中R9为-CH2-；-CH2-CH2-；或（III），R9和R8，连同R8所连接的氮原子，形成被V取代的哌嗪或吡咯烷环；V为-CO-NH-SO2-Ph，-SO2-NH-CO-Ph，-CH2OH，或式-R10U的基团（其中U为-COOH，四唑基，-CONHOH-或-SO3H；R10为键；C1至C6的烃亚基，-O-（C1至C3的烷基）-；-SO2NR11-CHR12-；-CO-NR11-CHR12-，或-NH-（CO）c-CH2-，其中c为0或1）。
• [EN] CYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DYSLIPIDAEMIA, ATHEROSCLEROSIS AND DIABETES, PHARMACEUTICAL COMPOSITIONS AND PREPARATION PROCESS<br/>[FR] COMPOSES CYCLIQUES UTILES DANS LE TRAITEMENT DE DYSLIPIDEMIE, D'ATHEROSCLEROSE ET DE DIABETES, COMPOSITIONS PAHARMACEUTIQUES ET PROCEDES DE PREPARATION ASSOCIES
  申请人：MERCK PATENT GMBH

  公开号：WO2000004011A1

  公开（公告）日：2000-01-27

  The present invention relates to cyclic compounds which can be used in the treatment of dyslipidaemia, atherosclerosis and diabetes, to processes for preparing these compounds. The compounds of the invention correspond to formula (I) wherein the radicals X, Y, R, R1, R2, R3, R4, R5, R6, R7 have meanings as given in claim 1.

  本发明涉及可用于治疗血脂异常、动脉粥样硬化和糖尿病的环状化合物，以及制备这些化合物的过程。本发明的化合物对应于式（I），其中基团X，Y，R，R1，R2，R3，R4，R5，R6，R7的含义如权利要求书1所述。
• Gastrin and cholecystokinin receptor ligands
  申请人：James Black Foundation Limited

  公开号：US06479531B1

  公开（公告）日：2002-11-12

  Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently ═N—, —N(R5)—═CH—, —S— or —O—. n is from 1 to 4; R1 is H or C1 to C15 hydrocarbyl R2 is selected from H, Me, Et, Pr and OH, R3 is selected from H, Me, Et and Pr; or (when n is greater than 1) each R3 is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C3 to C6 carbocylic ring, or R2 and R3 on the same carbon atom together represent an ═O group; R4 is C1 to C15 hydrocarbyl Z is —(NR7)a—CO—(NR8)b— (wherein a is 0 or 1, b is 0 or 1, —CO—NR7—CH2—CO—NR8—, —CO—O—, —CH2—CH2—, —CH═CH—, —CH2—NR8— or a bond; Q is —R9V, or (II), (wherein R9 is —CH2—; —CH2—CH2—; or (III), R9 and R8, together with the nitrogen atom to which R8 is attached, form a piperidine or pyrrolidine ring which is substituted by V; V is —CO—NH—SO2—Ph, —SO2—NH—CO—Ph, —CH2OH, or a group of the formula —R10U, (wherein U is —COOH, tetrazolyl, —CONHOH— or —SO3H; and R10 is a bond; C1 to C6 hydrocarbylene, —O—(C1 to C3 alkylene)—; —SO2NR11—CHR12—; —CO—NR11—CHR12—, or —NH—(CO)c—CH2—, c being 0 or 1).

  公式（I）的化合物及其药学上可接受的盐是胃泌素和/或胆囊收缩素受体的配体。X和Y分别是═N—，—N（R5）—═CH—，—S—或—O—。n为1到4；R1为H或C1到C15的烃基，R2从H、Me、Et、Pr和OH中选择，R3从H、Me、Et和Pr中选择；或（当n大于1时）每个R3独立地从H、Me、Et和Pr中选择，或相邻碳原子上的两个R3基团连接形成C3到C6的环烷基，或R2和同一碳原子上的R3一起代表═O基团；R4为C1到C15的烃基，Z为—（NR7）a—CO—（NR8）b—（其中a为0或1，b为0或1，—CO—NR7—CH2—CO—NR8—，—CO—O—，—CH2—CH2—，—CH═CH—，—CH2—NR8—或键；Q为—R9V，或（II），（其中R9为—CH2—；—CH2—CH2—；或（III），R9和R8与R8连接的氮原子一起形成被V取代的哌啶或吡咯烷环；V为—CO—NH—SO2—Ph，—SO2—NH—CO—Ph，—CH2OH，或公式—R10U的基团（其中U为—COOH、四唑基、—CONHOH—或—SO3H；R10为键；C1到C6的烃基亚甲基，—O—（C1到C3的亚甲基）—；—SO2NR11—CHR12—；—CO—NR11—CHR12—，或—NH—（CO）c—CH2—，其中c为0或1）。
• Dumont,C.; Vidal,M., Bulletin de la Societe Chimique de France, 1973, p. 2301 - 2312
  作者：Dumont,C.、Vidal,M.

  DOI：——

  日期：——